• The Magazine
  • Advertising
  • NLS Member
  • About Us
  • Contact
  • Subscribe
  • Sign in
  • Pharma
  • Medtech
  • Biotech
  • Science
  • Events
  • Careers
  • Jobs
  • Opinion & Debate
  • The Magazine
  • Advertising
  • NLS Member
  • About Us
  • Contact
Menu
  • Subscribe
  • Sign in

October 21, 2026

Science Impact 2026

Oslo, Norway

Spend a day with great science, innovation and networking opportunities at this meeting place for academia, hospitals, the institute sector, the public sector, start-ups and industry.​ The conference is a part of Oslo Innovation Week 2026.

21-10-2026

Share article on X
Share article on Linkedin
learn more about science impact 2026 here

Published: August 17, 2026

Top stories

Denmark – September 10, 2026

Copenhagen to get new quantum chip facility

Quantum Foundry Copenhagen and the Novo Nordisk Foundation are building a 5,300m² quantum chip fabrication facility in Copenhagen, aiming to strengthen Europe’s position in the global quantum race.

Business Award – September 10, 2026

They won the Nordic Star 2026 Pitch Competition

AAX Biotech AB won the prestigious Nordic Star Pitch Competition at the Nordic Life Science Days (NLSDays) 2026.

Profiles in Business – September 9, 2026

Olivier Duchamp-Giudicelli: NLSDays’ accidental founder looks back

After a full career building life science communities and now approaching something akin to retirement – meaning only cherry-picking the projects that appeal to him – French-born Olivier Duchamp-Giudicelli reflects on the accidental advent of NLSDays in 2014, and how partnering and dealmaking have changed over the years.

Clinical Trials – September 9, 2026

Novo Nordisk’s semaglutide moves obesity below threshold in nearly half of children in phase 3 trial

In the phase 3 STEP Young trial, 40.4% of children aged 6 to under 12 treated with once-weekly semaglutide were no longer classified as having obesity after 68 weeks, compared with none of those on placebo.

Follow NLS news
Follow us on XFollow us on LinkedinFollow us on Bluesky

Related posts

Denmark - September 10, 2026

Copenhagen to get new quantum chip facility

Quantum Foundry Copenhagen and the Novo Nordisk Foundation are building a 5,300m² quantum chip fabrication facility in Copenhagen, aiming to strengthen Europe's position in the global quantum race.

Business Award - September 10, 2026

They won the Nordic Star 2026 Pitch Competition

AAX Biotech AB won the prestigious Nordic Star Pitch Competition at the Nordic Life Science Days (NLSDays) 2026.

Profiles in Business - September 9, 2026

Olivier Duchamp-Giudicelli: NLSDays’ accidental founder looks back

After a full career building life science communities and now approaching something akin to retirement – meaning only cherry-picking the projects that appeal to him – French-born Olivier Duchamp-Giudicelli reflects on the accidental advent of NLSDays in 2014, and how partnering and dealmaking have changed over the years.

Clinical Trials - September 9, 2026

Novo Nordisk’s semaglutide moves obesity below threshold in nearly half of children in phase 3 trial

In the phase 3 STEP Young trial, 40.4% of children aged 6 to under 12 treated with once-weekly semaglutide were no longer classified as having obesity after 68 weeks, compared with none of those on placebo.

MedTech Business - September 9, 2026

Glycorex signs Brazilian distribution deal

Glycorex Transplantation has agreed a distribution deal with Grupo VIDA for its Glycosorb ABO technology in Brazil, as part of the Swedish medtech company's continued market expansion.

Event Highlights - September 8, 2026

NLSDays 2026: 3 x Voices from the exhibition floor

Our journalist Alexandra Hoegberg took the pulse of this year's NLSDays – the anticipation in the air, and the experiences and insights being shared.

Collaboration - September 8, 2026

HeartBeat.bio and Cubase Bio partner to advance 3D spatial transcriptomics

Vienna-based HeartBeat.bio and Stockholm-based Cubase Bio have been awarded roughly EUR 1 million in Eurostars funding to develop a 3D spatial profiling method for studying myocardial fibrosis and heart failure, combining human cardiac organoids with true 3D spatial transcriptomics technology.

Sign up to our newsletter: Nordic Life Science News!

I confirm that I want to subscribe to newsletters from Nordic Life Science and that Nordic Life Science has the right to save my email address. Read our privacy policy here

Read the latest issue!

Sign up for a subscription and read our latest digital issue today.

Sign up
Sign up

The leading life science news channel in the Nordic region.

© NLS Media Group AB – All rights reserved

Digital and print
  • The magazine
  • Subscribe
  • Newsletter
More information
  • About us
  • Contact
  • Advertising
Social media
  • LinkedIn
  • Bluesky
  • X
NLS Media Group AB

St Paulsgatan 13

118 46 Sweden

info@nlsnews.com

+46-8-588 941 51

  • Cookies
  • Data management and privacy policy

We Value Your Privacy

This site uses cookies

We use cookies to improve your experience on our site. By clicking "accept," you agree to our use of cookies.

Read more about our privacy policy

Only necessary
Accept All
Manage Cookies

Manage Cookies

functional

The "Functional" cookie category includes cookies that are essential for the smooth operation of our website and to enhance your browsing experience. These cookies enable various functionalities that make our site more user-friendly and efficient.

market

The "Market" cookie category encompasses cookies used to analyze and improve our marketing efforts. These cookies help us understand how you interact with our website and provide us with insights to optimize our content and advertisements, ensuring they are relevant to your interests.

personal

The "Personal" cookie category includes cookies that enhance the user experience by storing information about your preferences and interactions on our site. This allows us to tailor content and recommendations to your individual needs, providing a more personalized and engaging experience.